Clinical trials: Exudative Age Related Macular Degeneration
Neovascular Age-related Macular Degeneration
Zoledronic Acid as Adjuvant Therapy in Neovascular Age-related Macular Degeneration (Z-AMD)
A pilot study of zoledronic acid as adjuvant therapy to standard anti-vascular endothelial growth factor (anti-VEGF) treatment for neovascular age-related macular degeneration (AMD).
- Trial name
- Z-AMD (NCT04304755)
- Testing
- Zoledronic Acid 5 MG in 5 ML Injection
- Where
- 2 sites in Norway
- Volunteers
- 40 people
- Sponsor
- Oslo University Hospital
Neovascular Age Related Macular Degeneration
Safety Study of iSONEP (Sonepcizumab/LT1009) to Treat Neovascular Age-related Macular Degeneration
Age-related macular degeneration (AMD) is a disease that, in time, destroys the macula, which is the central part of the retina that gives sharp central vision.
- Trial name
- NCT00767949
- Testing
- iSONEP
- Where
- 5 sites in United States
- Volunteers
- 15 people
- Sponsor
- Lpath, Inc.
Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration
A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders
The study will evaluate the safety of ophthalmic bevacizumab in subjects diagnosed with a retinal condition that would benefit from treatment with intravitreal injection of bevacizumab, including: exudative age-related macular…
- Conditions
- Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration, Wet Macular Degeneration, BRVO - Branch Retinal Vein Occlusion
- Trial name
- NCT04516278
- Testing
- bevacizumab
- Where
- 20 sites in United States
- Volunteers
- 197 people
- Sponsor
- Outlook Therapeutics, Inc.
Age-Related Macular Degeneration
Effect of Squalamine Lactate Ophthalmic Solution, 0.2% in Subjects With Neovascular Age-Related Macular Degeneration
The purpose of this study is to evaluate anatomical and functional effect of combination therapy of Squalamine Lactate Ophthalmic Solution, 0.2% administered twice daily with monthly ranibizumab intravitreal injections in…
- Trial name
- NCT02511613
- Testing
- Squalamine Lactate Ophthalmic Solution, 0.2%, ranibizumab
- Where
- 4 sites in United States
- Sponsor
- Ohr Pharmaceutical Inc.
Macular Degeneration Choroidal Neovascularization
Faricimab Quarterly Maintenance for Neovascular Age Related Macular Degeneration
We aimed to investigate the success rate of a planned quarterly (every 12-16 weeks) faricimab injection schedule, following a disease inactivity achieved after initial 2-4 loading doses of faricimab, for nAMD to achieve stability…
- Trial name
- Fixed farcimab (NCT06742307)
- Testing
- Faricimab Injection [Vabysmo]
- Where
- Hong Kong
- Volunteers
- 40 people
- Sponsor
- Hospital Authority, Hong Kong
Age-Related Macular Degeneration
A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy
The objectives of this study are to evaluate the safety and efficacy of intravitreal administration of Fovista® administered in combination with Lucentis® compared to Lucentis® monotherapy in subjects with subfoveal choroidal…
- Trial name
- NCT01940900
- Testing
- E10030, ranibizumab
- Where
- 121 sites in United States, Argentina and 9 more
- Volunteers
- 627 people
- Sponsor
- Ophthotech Corporation
Neovascular Age-related Macular Degeneration
Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-2)
The purpose of this clinical study is to evaluate the efficacy and safety of two different levels of conbercept intravitreal (IVT) injection as compared to the approved vascular endothelial growth factor (VEGF) antagonist active…
- Trial name
- NCT03630952
- Testing
- 0.5 mg Conbercept Intravitreal Injection, 1.0 mg Conbercept Intravitreal Injection, 2.0 mg Aflibercept Intravitreal Injection
- Where
- 154 sites in United States, Bulgaria and 10 more
- Volunteers
- 1,157 people
- Sponsor
- Chengdu Kanghong Biotech Co., Ltd.
Wet Macular Degeneration
Pilot Study of Ranibizumab With and Without Ketorolac Eyedrops for Exudative Age-related Macular Degeneration
The addition of an anti-inflammatory agent could be a valid option for controlling choroidal neovascularization, as simply inhibiting VEGF addresses neither the multifactorial pathogenesis of choroidal neovascularization nor the…
- Trial name
- NCT02060604
- Testing
- Ketorolac + Ranibizumab, Ranibizumab
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- Università degli Studi di Brescia
Neovascular Age-related Macular Degeneration, Diabetic Macular Edema
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of D-4517.2 After Subcutaneous Administration in Healthy Participants
The primary objective of this study is to evaluate the safety and tolerability of D-4517.2 after single subcutaneous (SC) doses in healthy participants.
- Trial name
- NCT05105607
- Testing
- D-4517.2
- Where
- Australia
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Ashvattha Therapeutics, Inc.
Age Related Macular Degeneration
RBM-007 in Treatment naïve Exudative Age-related Macular Degeneration
This study is a single-center, open label, 4-month study, designed to evaluate the safety and treatment efficacy of RBM-007 in patients with intraretinal or subretinal edema due to previously untreated neovascular AMD.
- Trial name
- TEMPURA (NCT04895293)
- Testing
- RBM-007 Injectable Solution
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Maturi, Raj K., M.D., P.C.
Neovascular Age-Related Macular Degeneration
Study Evaluating the Treatment of OTX-TKI for Subjects With Neovascular Age-related Macular Degeneration
Evaluate the safety, tolerability, and efficacy of OTX-TKI for intravitreal use in subjects with Neovascular Age-Related Macular Degeneration
- Trial name
- NCT04989699
- Where
- 6 sites in United States
- Volunteers
- 21 people
- Sponsor
- Ocular Therapeutix, Inc.
Neovascular Age-related Macular Degeneration
Clinical Study of ALT-L9 to Determine Safety, Efficacy and Pharmacokinetics in Neovascular AMD
To evaluate the safety, efficacy and pharmacokinetics of repeated intravitreal administration of ALT-L9 2 mg/50uL compared with Eylea in patients with neovascular Age-related macular degeneration.
- Trial name
- NCT04058535
- Testing
- Eylea, ALT-L9
- Where
- South Korea
- Volunteers
- 28 people
- Sponsor
- Alteogen, Inc.
Age-related Macular Degeneration
Cytokeratin 8 Level in Age-related Macular Degeneration
The investigators will evaluate the concentrations of cytokeratin 8 in aqueous humor in eyes with exudative age-related macular degeneration (AMD) before therapy with intravitreal Ranibizumab, and identify associations with…
- Trial name
- NCT02707575
- Testing
- Ranibizumab
- Where
- 2 sites in South Korea
- Volunteers
- 58 people
- Sponsor
- Gangnam Severance Hospital
Non-Exudative Age Related Macular Degeneration
Phase II/III Study of the Efficacy and Safety of MacuCLEAR MC-1101 in Treating DryAge-Related Macular Degeneration
This is a Phase II/III,vehicle controlled, double masked, single center study. A single eye of 60 individuals with mild to moderate non-exudative Age-Related Macular Degeneration (AMD) will be randomly assigned to receive either…
- Trial name
- McCP2/3 (NCT02127463)
- Testing
- MC-1101, MC-1101 Vehicle
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- MacuCLEAR, Inc.
Neovascular Age-Related Macular Degeneration (nAMD)
Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration
The purpose of this study is to evaluate efficacy and safety of KHK4951 eye drops in patients with nAMD.
- Trial name
- NCT06116890
- Testing
- KHK4951, Aflibercept Injection
- Where
- 84 sites in United States, Australia and 2 more
- Volunteers
- 170 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Exudative Age-related Macular Degeneration
Bevacizumab for Neovascular Age-related Macular Degeneration
Age-related macular degeneration (AMD) is one of primary blinding eye disease among people over 65 years in China. The anti-VEGF antibody treatment is proved useful for Neovascular Age-related Macular Degeneration (nAMD) by many…
- Trial name
- NCT01306591
- Testing
- Bevacizumab 1, Bevacizumab
- Where
- China
- Volunteers
- 210 people
- Sponsor
- Peking University People's Hospital
Macular Edema
Ranibizumab Plus Indomethacin
To evaluate whether indomethacin eyedrops plus intravitreal ranibizumab (IVR) provides additional benefit over IVR monotherapy for treatment of choroidal neovascularization (CNV) in age-related macular degeneration.
- Trial name
- NCT03261635
- Testing
- Ranibizumab Injection, Indomethacin
- Volunteers
- 58 people
- Sponsor
- Università degli Studi di Brescia
Neovascular Age-related Macular Degeneration(nAMD)
Prospective, Single Arm, Observational Study of Faricimab in the Treatment of Neovascular Age-related Macular Degeneration (nAMD)
Evaluate the benefit of faricimab (4 loading doses + PRN) on best-corrected visual acuity in patients with nAMD. Evaluate the safety and anatomical improvement of faricimab (4 loading doses + PRN) in patients with nAMD.
- Trial name
- NCT07581782
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Sun Yat-sen University
Macular Degeneration, Maculopathy, Age-Related
Anecortave Acetate in Subfoveal Choroidal Neovascularization (CNV) Due to Wet Age-Related Macular Degeneration (AMD)
The purpose of this study was to evaluate anecortave acetate compared to placebo for maintenance of visual acuity after 24 months of treatment in patients with subfovial choroidal neovascularization (CNV) due to exudative…
- Conditions
- Macular Degeneration, Maculopathy, Age-Related, Age-Related Maculopathies, Age-Related Maculopathy
- Trial name
- NCT00051129
- Testing
- Anecortave Acetate 15 mg sterile suspension, Anecortave Acetate Vehicle
- Volunteers
- 291 people
- Sponsor
- Alcon Research
Retinal Vasculitis
Incidence of Retinal Vasculitis Among Patients Receiving Aflibercept: A US Real-World Evidence Study
This study will describe and estimate the incidence of Retinal Vasculitis (RV) events among patients and patient eyes receiving aflibercept intravitreal (IVT) (Eylea®, aflibercept 2mg) therapy in US clinical practice.
- Trial name
- NCT07105228
- Testing
- aflibercept 2mg
- Where
- United States
- Volunteers
- 290,000 people
- Sponsor
- Regeneron Pharmaceuticals